Abstract:Osimertinib is a 3rd-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFR-mutated (EGFRm) and EGFR T790M resistance mutations, and has demonstrated efficacy in NSCLC CNS metastases. In the phase III FLAURA study (NCT02296125), osimertinib resulted in significant progression-free survival (PFS) benefit (primary endpoint; datacut off [DCO] 12 June 2017) over comparator EGFR-TKI (HR 0.46, p < 0.001). Overall survival (OS) data were immature (25% maturity) at that time. Here, we report the final OS analysis (58% maturity).Eligible patients (pts): ≥18 years (Japan: ≥20), treatment-naïve with Ex19del/L858R EGFRm advanced NSCLC; WHO performance status 0–1. Pts with stable CNS metastases not requiring steroids for ≥2 weeks were allowed. Pts were randomised 1:1 to osimertinib 80 mg once daily (qd) orally (po) or comparator EGFR-TKI (gefitinib 250 mg qd/erlotinib 150 mg qd po), stratified by mutation status (Ex19del/L858R) and race (Asian/non-Asian). Crossover was allowed for pts in the comparator EGFR-TKI arm upon central confirmation of progression and T790M positivity. Primary endpoint: PFS by RECIST v1.1, per investigator. OS was a secondary endpoint. DCO 25 June 2019.Globally, 556 pts were randomised to osimertinib (n = 279) or comparator EGFR-TKI (n = 277). Per study protocol, 70 (25%) pts crossed over from comparator EGFR-TKI to osimertinib. Osimertinib significantly improved OS vs comparator EGFR-TKI. All causality AEs, per investigator: osimertinib, 98% (grade ≥3, 42%); comparator EGFR-TKI, 98% (grade ≥3, 47%). AEs leading to discontinuation: osimertinib, 15%; comparator EGFR-TKI, 18%. The safety profile appears consistent with previously reported data. LBA5_PROS for patients in the full analysis set was analysed using a log rank test (stratified by race and mutation type) for generation of the p-value and using the Breslow approach for handling ties. The median OS with 95% confidence intervals were calculated by Kaplan Meier technique. For statistical significance, a 2-sided p-value of less than 0.0495, as determined by the O'Brien-Fleming approach was required due the previous interim analysis.*Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.LBA5_PROS for patients in the full analysis set was analysed using a log rank test (stratified by race and mutation type) for generation of the p-value and using the Breslow approach for handling ties. The median OS with 95% confidence intervals were calculated by Kaplan Meier technique. For statistical significance, a 2-sided p-value of less than 0.0495, as determined by the O'Brien-Fleming approach was required due the previous interim analysis.*Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.Osimertinib provided a statistically significant and clinically meaningful improvement in OS vs comparator EGFR-TKI in first-line pts with EGFRm advanced NSCLC.NCT02296125.Natalie Griffiths, PhD, from iMed Comms, an Ashfield Company; funded by AstraZeneca.AstraZeneca.AstraZeneca.S.S. Ramalingam: Honoraria (self), Advisory / Consultancy: AstraZeneca, Amgen, Bristol-Myers Squibb, Merck, Roche/Genentech, Loxo, Nektar, Tesaro; Research grant / Funding (institution): AstraZeneca, Amgen, Bristol-Myers Squibb, Merck, Tesaro, Advaxis, Takeda. J.E. Gray: Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Takeda; Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Celgene, Takeda; Research grant / Funding (institution): Array, Merck, AstraZeneca, Genentech, Boehringer Ingelheim, Bristol-Myers Squibb. Y. Ohe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca, Chugai, Dainippon Lilly, Ono, BMS Japan, Daiichi Sankyo, BI, Bayer, Ignyta, Pfizer, MSD, Taiho, Novartis, Kyorin, Kyowa Hakko Kirin, Takeda, Celltrion, Kissei, Amgen, Janssen, ROXO. B.C. Cho: Honoraria (institution), Advisory / Consultancy: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly, Takeda; Speaker Bureau / Expert testimony: Novartis; Research grant / Funding (institution): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Licensing / Royalties: Champions Oncology; Shareholder / Stockholder / Stock options: TheraCanVac Inc.. J. Vansteenkiste: Research grant / Funding (institution): MSD; Advisory / Consultancy: Apotex, AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Roche; Speaker Bureau / Expert testimony: AstraZeneca, BMS, MSD, Roche. C. Zhou: Honoraria (self): Roche, Eli Lilly, Boehringer Ingelheim, Merck, Hengrui and Qiru. B. Chewaskulyong: Honoraria (self), Advisory / Consul<p>-Abstract Truncated-</p>

440O Afatinib (A) Vs Gefitinib (G) in Patients (pts) with EGFR Mutation-Positive (egfrm +) NSCLC: Overall Survival (OS) Sdata from LUX-Lung 7 (LL7)

Afatinib (A) Vs Gefitinib (G) in Patients with EGFR Mutation-Positive (egfrm+) NSCLC: Updated OS Data from the Phase IIb Trial LUX-Lung 7 (LL7)

445P Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (pts) with NSCLC Harboring EGFR Mutations (mut): Subgroup Analyses by Race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

446PD Second-line Afatinib Vs Erlotinib for Patients with Squamous Cell Carcinoma of the Lung in LUX-Lung 8: Analysis of Tumor and Serum Biomarkers

LUX-Lung 8 Phase III Trial: Analysis of Long-Term Response to Second-Line Afatinib in Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung

443PPhase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes

Lux-Lung 8: A Global Phase Iii Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment in Patients (pts) with Advanced Squamous Cell Carcinoma (scc) of the Lung Following First-Line Platinum-Based Chemotherapy

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

OA23.05 First-Line Afatinib Versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

First-line Afatinib (A) Vs Gefitinib (G) for Patients (pts) with EGFR Mutation Positive (egfrm+) NSCLC (Lux-Lung 7): Patient-reported Outcomes (pros) and Impact of Dose Modifications on Efficacy and Adverse Events (Aes).

Lux-Lung 8: A Randomized, Open-Label, Phase Iii Trial of Afatinib Vs. Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung As Second-Line Therapy Following First-Line Platinum-Based Chemotherapy

Afatinib Vs Gefitinib in Patients (pts) with EGFR Mutation-Positive (egfrm+) NSCLC: Overall Survival (OS) Data from LUX-Lung 7 (LL7)

P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy: Topic: Phase II + NK

Afatinib Versus Gefitinib As First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-cell Lung Cancer (Lux-Lung 7): a Phase 2B, Open-Label, Randomised Controlled Trial

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

LUX-Lung 6: Patient-reported Outcomes (pros) from a Randomized Open-Label, Phase III Study in First-Line Advanced NSCLC Patients (pts) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations.

Afatinib Versus Erlotinib As Second-Line Treatment of Patients (pts) with Advanced Lung Squamous Cell Carcinoma (SCC): Final Analysis of the Global Phase III LUX-Lung 8 (LL8) Trial.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial